HOUSTON, April  03, 2026  (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO) announced that its annual report(10-K) for the fiscal year ending December 31, 2025, filed on March 11, 2026, includes an audit opinion from

Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans

Impact BioMedical Faces Going Concern Audit While Pursuing Merger

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>HOUSTON, April  03, 2026  (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO) announced that its annual report(10-K) for the fiscal year ending December 31, 2025, filed on March 11, 2026, includes an audit opinion from</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Impact BioMedical&#039;s recent audit raised a &#039;going concern&#039; qualification, highlighting financial vulnerabilities. With an upcoming merger with Dr. Ashley&#039;s Ltd. expected by July 2026, securing additional financing is critical to stabilize operations and boost investor confidence.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>IBO&#039;s annual report includes a &#039;going concern&#039; qualification from auditors.</li><li>The announcement is mandated by NYSE regulations for such audit opinions.</li><li>IBO continues plans to merge with Dr. Ashley&#039;s Ltd. by July 1, 2026.</li><li>The merger is crucial for IBO&#039;s financial stability amid going concern issues.</li><li>Future funding is essential for IBO to overcome auditor&#039;s expressed doubts.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Impact BioMedical Inc. (IBO)</strong>: Facing significant financial scrutiny due to audit opinion.</li><li><strong>Dr. Ashley&#039;s Ltd. (N/A)</strong>: Merger may aid IBO in addressing financial concerns.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news fits under &#039;Corporate Developments&#039; due to the important merger and financial assessment critical for IBO&#039;s future.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>The &#039;going concern&#039; qualification may trigger negative investor sentiment and stock sell-offs.</li><li>Completion of the merger could stabilize IBO&#039;s financial position and improve outlook.</li><li>Securing financing is crucial; failure to do so may lead to further decline.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>10-K report filed on March 11, 2026.</li><li>Audit opinion from Grassi &amp; Co. highlighted a &#039;going concern&#039; qualification.</li><li>Merger with Dr. Ashley&#039;s Ltd. projected to complete by July 1, 2026.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Investors should closely monitor IBO&#039;s merger progress and funding status for potential volatility.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>HOUSTON, April  03, 2026  (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/IBO">IBO</a>) announced that its annual report(10-K) for the fiscal year ending December 31, 2025, filed on March 11, 2026, includes an audit opinion from Grassi &amp; Co., CPAs, P.C. that contains a &#34;going concern&#34; qualification. This announcement is made pursuant to NYSE American LLC Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph and does not represent any change or amendment to the Company's financial statements for the year ended December 31, 2025.</p>  <p>Again, this announcement does not represent any change or amendment to the Company's financial statements or to its Annual Report on Form 10-K for the year ended December 31, 2025.</p>  <p>Separately, Impact Biomedical continues with strategic plans to merge with Dr. Ashley's Ltd. (<a href="https://www.globenewswire.com/Tracker?data=n6hUCZa_mBs1XdIOSCI8KdWD96Sof-5jRbIxVuPBJ3-nZFHGMmL_kJxaudB-kWMg6AZZs1cjXtqc5LqQplFnE-_YQQkpA_oac1NLxuwnw3j4X5IVoLSpNsvwvxJ4Bs29idv1_cv3z5tWnJXe18EchgpGO7hwu6wuWdjTEePouneb2WBLXcjOdV1WQj5kb8QE" rel="nofollow" target="_blank">here</a>), projected to be completed by July 1, 2026.</p>  <p align="justify"><strong>About Impact Biomedical Inc.</strong></p>  <p align="justify">Impact Biomedical Inc. (IBIO) discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships.</p>  <p><strong>Safe Harbor Statement</strong><br></br>This press release contains forward-looking statements. These statements involve risks and uncertainties, including the company&#39;s ability to close its pending merger and secure additional financing to address the going concern doubt expressed by its auditors. Actual results may differ materially.</p>  <p><strong>Investor Relations:</strong><br></br><a href="https://www.globenewswire.com/Tracker?data=BJV7GwZY-G1chlSS5Dt-MiYZ6kvcV7kLA3Ms4y9DaBvBGbmo52tcgPO74epmeU9dVxPBZUl6FbD0YFKzJFiQ-PfG1xqJkajjfcNJTStp0Yc43sGOeU1wLren8wwxE-Er8H19nGibRSYxFlg5B8jsM0DiPTPKIr3UxdLbwuR7It7QTsPRax5M5tG3ohlov7MH5UgyU0IOnABSGqJQfp4nktxdDBR8e7V3z3SP7Tu0fLTjYwNKx3Tidu0PfB4E_CQ9pTyCotLfGNvwm-DwSC6SJA==" rel="nofollow" target="_blank">info@impactbiomedinc.com</a></p>  <p><a href="https://www.globenewswire.com/Tracker?data=ymmDP4SY38sRF5mcz_C9wD6t_hvwdK2_IaBiIEOlyfHNyDGBG1WnE6tCkrwhSGEE1KnsMrDtc1Yti3KgmK0QnwzGkJtn6nY47LRjsVsSQlc=" rel="nofollow" target="_blank">www.impactbiomedinc.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY4NDAzMCM3NTE5Mjk2IzIyNjQyMjI="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NDQyZDMyOTMtYjI2YS00YmVlLWFlZmMtMTIwYWI2MGYwNTJhLTEyNzU3NzItMjAyNi0wNC0wMy1lbg==/tiny/IMPACT-BIOMEDICAL-INC.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/5eb787ba-e418-4ec9-ab20-690ee7931414"><img src="https://ml.globenewswire.com/media/5eb787ba-e418-4ec9-ab20-690ee7931414/small/impact-biomedical-inc-logo-jpg.jpg" border="0" width="150" height="68" alt="Primary Logo"></img></a></p>

Impact BioMedical's recent audit raised a 'going concern' qualification, highlighting financial vulnerabilities. With an upcoming merger with Dr. Ashley's Ltd. expected by July 2026, securing additional financing is critical to stabilize operations and boost investor confidence.

Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News